查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703325

鎮咳藥市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、給藥途徑、年齡層、最終用戶、地區和競爭細分，2020 年至 2030 年預測

Antitussive Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Route of Administration, By Age Group, By End-User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球鎮咳藥市場價值為 16 億美元，預計在預測期內將穩定成長，到 2030 年的複合年成長率為 5.20%。全球鎮咳藥市場正在經歷持續成長，主要原因是呼吸系統疾病盛行率上升、老年人口增加以及醫療保健可近性的提高。鎮咳藥或止咳藥對於治療與上呼吸道感染 (URTI)、慢性阻塞性肺病 (COPD)、氣喘、支氣管炎和病毒後症候群等疾病相關的急性和慢性咳嗽至關重要。

市場概覽
預測期 2026-2030
2024年市場規模 16億美元
2030年市場規模 21.7億美元
2025-2030 年複合年成長率 5.20%
成長最快的領域 周邊作用藥物
最大的市場 北美洲

該市場受益於消費者對非處方 (OTC) 和處方鎮咳藥的強勁需求，其中領先的製藥公司和新興行業參與者做出了重大貢獻。持續的研究和開發 (R&D) 工作以及藥物配方的進步正在塑造競爭態勢並促進產品創新。

關鍵市場促進因素

呼吸系統疾病盛行率上升

主要市場挑戰

監管障礙和嚴格的核准

主要市場趨勢

轉向非鴉片類和非可待因製劑

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：鎮咳藥市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別（周邊作用藥物、中樞作用藥物、其他）
    • 依給藥途徑（吸入、口服、其他）
    • 依年齡層別（老年人、兒童、成人）
    • 按最終使用者（家庭護理、醫院和專科診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美鎮咳藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鎮咳藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太鎮咳藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲鎮咳藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲鎮咳藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球鎮咳藥市場：SWOT 分析

第 14 章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Bayer AG
  • Ipca Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hikma Pharmaceuticals PLC
  • Unique Pharmaceuticals Limited
  • Cipla Inc.
  • Viatris Inc.
  • Aurobindo Pharma

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17246

Global Antitussive Drugs Market was valued at USD 1.60 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.20% through 2030. The Global Antitussive Drugs Market is experiencing sustained growth, primarily driven by the rising prevalence of respiratory diseases, an expanding elderly population, and improved healthcare accessibility. Antitussive drugs, or cough suppressants, are essential in managing acute and chronic coughs linked to conditions such as upper respiratory tract infections (URTIs), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and post-viral syndromes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.60 Billion
Market Size 2030USD 2.17 Billion
CAGR 2025-20305.20%
Fastest Growing SegmentPeripherally Acting Drugs
Largest MarketNorth America

This market benefits from strong consumer demand for both over-the-counter (OTC) and prescription-based antitussive medications, with major contributions from leading pharmaceutical corporations and emerging industry players. Ongoing research and development (R&D) efforts, alongside advancements in drug formulations, are shaping competitive dynamics and fostering product innovation.

Key Market Drivers

Rising Prevalence of Respiratory Diseases

The rising prevalence of respiratory diseases is one of the most significant drivers fueling the expansion of the Global Antitussive Drugs Market. With an increasing number of people experiencing respiratory illnesses, the demand for cough suppressants and related medications is witnessing steady growth. Each year, chronic obstructive pulmonary disease (COPD) claims over 3 million lives, yet it remains significantly underprioritized in global healthcare discussions. Affecting more than 380 million people worldwide, COPD is the fourth leading cause of death, imposing a severe economic and healthcare burden. Despite its widespread impact on patients, caregivers, and healthcare systems, the disease continues to receive disproportionately low attention and funding compared to other major noncommunicable diseases. Chronic and acute respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, pneumonia, tuberculosis (TB), and post-viral cough syndromes, are becoming more prevalent worldwide. In 2023, tuberculosis (TB) affected an estimated 10.8 million people globally, including 6.0 million men, 3.6 million women, and 1.3 million children, highlighting its widespread impact across demographics. Present in every country and affecting all age groups, TB continues to pose a significant public health challenge. These conditions often manifest with persistent coughing, requiring effective antitussive (cough suppressant) treatments.

Key Market Challenges

Regulatory Hurdles and Stringent Approvals

One of the primary challenges in the antitussive drugs market is the rigorous regulatory environment governing pharmaceuticals. To ensure safety and efficacy, regulatory agencies such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) impose stringent approval processes for new antitussive drugs.

Developing and bringing a new antitussive drug to market involves extensive clinical trials, data submission, and regulatory reviews. The process is time-consuming and costly, with no guarantee of approval. Companies may face delays, increased development costs, or even the rejection of their drug candidates, impacting market entry.

Key Market Trends

Shift Towards Non-Opioid and Non-Codeine Formulations

One of the prominent trends in the antitussive drugs market is the increasing preference for non-opioid and non-codeine formulations. This shift is primarily driven by concerns related to the addictive potential and side effects associated with opioid-based antitussive drugs.

Regulatory Scrutiny: Regulatory agencies like the FDA have imposed stricter controls and monitoring of opioid-based medications due to their potential for abuse and addiction. This has led to a reduced appetite among healthcare providers to prescribe such drugs. Patient Safety: Patient safety and minimizing the risk of opioid misuse have become paramount concerns. Non-opioid alternatives are seen as safer options for managing coughing, especially in pediatric and vulnerable patient populations.

Advances in pharmaceutical research have led to the development of non-opioid antitussive medications that offer comparable efficacy in suppressing coughing without the risk of opioid-related complications. This has fueled the market demand for non-opioid alternatives.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Bayer AG
  • Ipca Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hikma Pharmaceuticals PLC
  • Unique Pharmaceuticals Limited
  • Cipla Inc.
  • Viatris Inc.
  • Aurobindo Pharma

Report Scope:

In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antitussive Drugs Market, By Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs
  • Others

Antitussive Drugs Market, By Route of Administration:

  • Inhalational
  • Oral
  • Others

Antitussive Drugs Market, By Age Group:

  • Geriatric
  • Pediatric
  • Adult

Antitussive Drugs Market, By End-User:

  • Homecare
  • Hospitals & Specialty Clinics
  • Others

Antitussive Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.

Available Customizations:

Global Antitussive Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Antitussive Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
    • 5.2.2. By Route of Administration (Inhalational, Oral, Others)
    • 5.2.3. By Age Group (Geriatric, Pediatric, Adult)
    • 5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Antitussive Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Age Group
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antitussive Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Age Group
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Antitussive Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Age Group
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Antitussive Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Age Group
        • 6.3.3.2.4. By End User

7. Europe Antitussive Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Age Group
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antitussive Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Age Group
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Antitussive Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Age Group
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Antitussive Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Age Group
        • 7.3.3.2.4. By End User
    • 7.3.4. France Antitussive Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Age Group
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Antitussive Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Age Group
        • 7.3.5.2.4. By End User

8. Asia-Pacific Antitussive Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Age Group
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antitussive Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Age Group
        • 8.3.1.2.4. By End User
    • 8.3.2. India Antitussive Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Age Group
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Antitussive Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Age Group
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Antitussive Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Age Group
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Antitussive Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Age Group
        • 8.3.5.2.4. By End User

9. South America Antitussive Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Age Group
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antitussive Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Age Group
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Antitussive Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Age Group
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Antitussive Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Age Group
        • 9.3.3.2.4. By End User

10. Middle East and Africa Antitussive Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Age Group
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antitussive Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Age Group
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Antitussive Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Age Group
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Antitussive Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Age Group
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Antitussive Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Intas Pharmaceuticals Ltd.
  • 14.3. Bayer AG
  • 14.4. Ipca Laboratories Ltd.
  • 14.5. F. Hoffmann-La Roche Ltd.
  • 14.6. Hikma Pharmaceuticals PLC
  • 14.7. Unique Pharmaceuticals Limited
  • 14.8. Cipla Inc.
  • 14.9. Viatris Inc.
  • 14.10.Aurobindo Pharma

15. Strategic Recommendations

16. About Us & Disclaimer